2025年8月27-28日，第十九届沙利文全球增长、科创与领导力峰会暨第四届新投资大会于上海静安香格里拉酒店盛大举行。

On August 27-28, the 19th FROST & SULLIVAN Global Growth, Innovation & Leadership Summit and the 4th New Investment Conference were grandly held at the Shanghai Jing'an Shangri-La Hotel.

恒医生物凭借其在重组胶原蛋白领域的前沿创新与行业引领作用，获颁大会重磅荣誉——“全球重组胶原蛋白技术创新领导奖”，成为本届峰会中备受瞩目的生物科技企业之一。

With its cutting-edge innovation and industry leadership in the field of recombinant collagen, EVERON HEALTHCARE won the "Global Recombinant Collagen Technology Innovation Leadership Award" and became one of the high-profile biotechnology enterprises in this summit.

相关领域唯一获沙利文GIL奖项

晚宴上，2025年度沙利文增长、科创与领导力全球奖、中国奖及最佳实践奖重磅揭晓。恒医生物斩获2025年度「全球重组胶原蛋白技术创新领导奖」

At the gala dinner, the prestigious 2025 Frost & Sullivan Global Awards for Growth, Innovation & Leadership, China Awards, and Best Practices Awards were unveiled. EVERON HEALTHCARE was honored with the 2025 “Global Innovation Leadership Award for Recombinant Collagen Technology.”

恒医生物创始人&首席执行官杨济霖先生上台领奖

沙利文GIL奖迄今已表彰全球超5000家杰出公司，其权威性与公正性广受金融、投资及产业界认可。

The Frost & Sullivan GIL Award has recognized over 5,000 outstanding companies worldwide to date, with its authority and impartiality widely acknowledged across the financial, investment, and industrial sectors.

沙利文高级副总裁兼马来西亚负责人Hazmi Yusof和中国肝炎防治基金会理事长、沙利文全球专家顾问团专家顾问2024沙利文大中华区特别贡献奖得主王宇教授为恒医生物颁奖

恒医生物凭借“重组人源化三螺旋结构胶原蛋白”技术体系，从全球参评企业中脱颖而出，成为本年度该细分技术领域内唯一获此殊荣的企业，彰显了国际机构对其科技实力与创新能力的充分肯定。

EVERON HEALTHCARE distinguished itself among global competitors with its “recombinant humanized triple-helix collagen” technology system, becoming the sole Chinese enterprise honored in this specialized technical field this year. This accolade underscores international recognition of the company's scientific capabilities and innovative prowess.

两大展位多维呈现核心成果

会议期间，恒医生物于会场设立双展位，产品与技术全线亮相。

During the conference, EVERON HEALTHCARE established a dual exhibition booth at the venue, showcasing its full range of products and technologies. 

系统性展出包括“重组人源冻干纤维”、“重组人源化三螺旋III型胶原蛋白原料”在内的等多款明星产品。

The systematic display featured multiple flagship products, including “Recombinant Human-Derived Lyophilized Fibrin” and “Recombinant Human-Derived Triple-Helix Type III Collagen Raw Material.”

The EVERON HEALTHCARE booth was bustling with visitors, all gathered to explore the latest frontiers in biotechnology.

高峰论坛发表主题演讲

张春莉博士从技术原理、产品开发及产业化落地等多维度分享重组人源化三螺旋胶原蛋白的突破与思考。

Dr. Ann Zhang shared insights on the breakthroughs and considerations surrounding recombinant humanized triple-helix collagen from multiple perspectives, including technical principles, product development, and industrial implementation.

此次获奖不仅是国际对恒医生物现阶段成果的认可，更是对其持续创新路径的有力背书。

This award not only signifies international recognition of EVERON HEALTHCARE's current achievements but also serves as a strong endorsement of its ongoing commitment to innovation.

未来，恒医生物将立足全球视野，持续推动重组胶原蛋白技术应用突破，深化重组人源化胶原蛋白在医疗美容、创面修复、再生医学等领域的研发与应用，与全球合作伙伴共塑生物材料增长新极。

In the future, EVERON HEALTHCARE will maintain a global perspective, continuously driving breakthroughs in recombinant collagen technology applications. We will further deepen the research and application of recombinant humanized collagen in medical aesthetics, wound repair, regenerative medicine, and other fields, collaborating with global partners to shape new growth poles in biomaterials.